BPG is committed to discovery and dissemination of knowledge
Correspondence
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 126177
Published online Nov 27, 2026. doi: 10.4254/wjh.126177
Letter to the Editor: Unpacking the active ingredient of home-based metabolic dysfunction-associated steatotic liver disease care: Separating incentive from surveillance effects
Ze-Cheng Yang, Jing-Tan Wang, Zhi-Gang Ren
Ze-Cheng Yang, Zhi-Gang Ren, Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Jing-Tan Wang, Department of Clinical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Yang ZC was responsible for conceptualization, initial draft preparation, and manuscript revision; Wang JT was responsible for review and revision of the manuscript; Ren ZG was responsible for conceptualization, review and critical revision of the manuscript; and all the authors have read and approved the final manuscript.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Supported by the National Natural Science Foundation of China, No. 82470654; the Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project, No. 2025ZD01906305; and the Henan Zhongyuan Medical Science and Technology Innovation and Development Foundation, No. ZYYC202301ZD.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Corresponding author: Zhi-Gang Ren, MD, PhD, Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, Henan Province, China. fccrenzg@zzu.edu.cn
Received: July 29, 2026
Revised: September 4, 2026
Accepted: October 14, 2026
Published online: November 27, 2026
Processing time: 114 Days and 22 Hours
Core Tip

Core Tip: This letter examines the timeliness-incentive home-based metabolic dysfunction-associated steatotic liver disease trial by Mei et al. The intervention bundled psychological incentives with added diagnostic surveillance, which constituted a material reward. These two components therefore overlap, so the benefit cannot be attributed to the theory alone. We recommend attention-matched controls, multiphase optimization strategy factorial designs, and prospective recording of contact frequency and patients’ awareness of fibrosis status. Because the same overlap recurs in multicomponent behavioral and digital interventions, the lesson extends beyond this trial.

Write to the Help Desk